MedTrace Logo

Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib

NCT00526669 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2016-01-29

Study results available
· View outcomes & findings →

Summary

The study will determine if changes in expression of markers involved in the 5-FU pathways are associated with response to treatment with the combination of lapatinib and capecitabine independent of tumor erbB2 status.

Conditions

  • Neoplasms, Gastrointestinal Tract

Interventions

DRUG

Lapatinib and Capecitabine

oral lapatinib (1250mg) administered as a monotherapy run-in followed by its combination with capecitabine

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2011-04-30
Completion
2015-01-31

Countries

  • United States
  • Canada
  • Mexico
  • Russia
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00526669 on ClinicalTrials.gov